GlassScriptPhysician profile
Candice Pacheco
NPI 1548682230
$701.32
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $155.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $140.70 | 2021-2022 | |
| Pfizer INC. | $103.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.23 | 2021-2022 | |
| Abbvie INC. | $63.24 | 2021-2022 | |
| Amgen INC. | $41.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $24.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.32 | 2021 | |
| Medline Industries LP | $20.47 | 2022 | |
| Hologic Sales and Service, LLC | $17.18 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.83 | 2022 | |
| Lilly USA, LLC | $12.97 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.